The ongoing debate over specialty drugs — reflecting conflicting motives of buyers and sellers — neglects important insights about the impact of these new technologies, their value to society, and the economics of medical R&D.
We propose an approach to health insurance reform that promotes high-quality, fiscally sustainable health care for all. Our solution is a departure from both the current system and the Affordable Care Act reforms that begin in 2014.
Reducing end-of-life costs will do little to curb the growth in Medicare spending overall. But end-of-life care provision should be reformed to match the values of patients.
Incorporating the effects of health into an analysis of economic disparities in America dramatically affects our understanding of wealth levels across groups–particularly across races.
New medical technologies are often argued to be a leading force behind the growth in health care spending.
Anupam B. Jena and Tomas J. Philipson argue that further use of cost-effectiveness analysis to curb health care spending may do more harm than good.